New drug combo aims to outperform chemo in Tough-to-Treat stomach cancer
Disease control
Completed
This phase 3 trial tested whether a combination of two drugs, regorafenib and nivolumab, helps people with advanced gastro-oesophageal cancer live longer than standard chemotherapy. The study included 462 adults whose cancer had stopped responding to prior treatments. The goal wa…
Phase: PHASE3 • Sponsor: Australasian Gastro-Intestinal Trials Group • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC